Results of a clinical trial of an EGFR-agent called osimertinib was recently published in the New England Journal of Medicine. A short video was made to discuss this important trial. Based on the results, it is expected that the FDA will approve osimertinib as first-line treatment for patients with EGFR-mutated lung cancer. The drug is already approved (brand name Tagrisso) for patients whose lung cancer has the T790M mutation. nejm.org/do/10.1056/NEJMdo0...
Video about a lung cancer clinical tri... - Lung Cancer Support
Video about a lung cancer clinical trial by the New England Journal of Medicine
Written by
MFH_Advocate
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
First Targeted Adjuvant Therapy for EGFR Non Small Cell Lung Cancer (stage IB-IIIA)
On December 18th, 2020, the Food and Drug Administration (FDA) approved Tagrisso (osimertinib) for...
What It's Like to Be in a Lung Cancer Clinical Trial - Part One, Background Information
Have you ever thought about participating in a lung cancer clinical trial? The thought of taking an...
Study presented at the European Society for Medical Oncology (ESMO) Congress may mean a new way to treat patients with stage 3 lung cancer
This past week, results of some key studies were presented at a major meeting in Spain. One study,...
EGFR mutations on exon 20 and exon 21
Hello,
I'm 42M, and I've just been diagnosed with stage 4 lung cancer.
My PD-L1 is between 30 and...
The Side Effect They Don’t Tell You About: Lung Cancer, Treatment, and Your Love Life
There is a very common family of side effects that can result from lung cancer treatment, indeed...
Related Posts
TRANSCRIPT: Ask Us Anything about Precision Medicine and Lung Cancer with Dr. Howard Jack West and Janet Freeman-Daily- What It's Like to Be in a Lung Cancer Clinical Trial - Part Two, The Clovis Pharmaceuticals Phase II Trial for CO-1686
- A new drug for ALK-positive lung cancer approved today
Be part of the campaign to raise awareness of lung cancer!- FDA Approves Tecentriq for First-Line Treatment of Metastatic NSCLC with High PD-L1 Expression
